• About us
• Contact

Advertisement

Person › Details

Susanne Schaffert (Novartis Oncology (business unit, since 7/16))

Schaffert, Susanne (Novartis 201901–2022 CEO of Oncology Business Unit joined Novartis >20 years ago RETIRED 2022)

 

	Organisation	Novartis Oncology (business unit, since 7/16)
	Group	Novartis (Group)
	Product	cancer drug
	Product 2	oncology

Record changed: 2024-07-17

Advertisement

More documents for Susanne Schaffert

• [1] Galapagos N.V.. (6/12/23). "Pressemitteilung: Galapagos Appoints Dr. Susanne Schaffert as Non-executive Independent Director to Its Board". Mechelen....
• [2] Rubius Therapeutics, Inc.. (7/14/22). "Press Release: Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors". Cambridge, MA....
• [3] Novartis AG. (12/20/21). "Press Release: Novartis Strengthens Immunotherapy Pipeline with Option, Collaboration and License Agreement with BeiGene for TIGIT inhibitor Ociperlimab". Basel....
• [4] Novartis AG. (1/11/21). "Press Release: Novartis Expands Oncology Pipeline with In-licensing of Tislelizumab from BeiGene". Basel....
• [5] Novartis AG. (5/24/19). "Press Release: FDA Approves Novartis Piqray - the First and Only Treatment Specifically for Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.